NCT07740239 A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial
| NCT ID | NCT07740239 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tampere University Hospital |
| Condition | Pelvic Fracture |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,050 participants |
| Start Date | 2024-11-13 |
| Primary Completion | 2030-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,050 participants in total. It began in 2024-11-13 with a primary completion date of 2030-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this prospective multicentre study that recruits altogether 1500 older patients from the university hospitals of Tampere, Kuopio, and Oulu is to explore the clinical significance and detection of causes of generalized vulnerability. The objectives are: O1 - Establish the prevalence of causes of generalized vulnerability among patients diagnosed with severe yet non-malignant diseases and local/locally advanced and advanced cancers, O2 - Study how causes of generalized vulnerability affect the time between the diagnosis and the adoption of a fully palliative treatment line, overall survival, and patient-reported quality of life in older adults severe diseases, and O3 - Evaluate how screening tools commonly used in patients without cancer perform in screening for causes of vulnerability in older adults with cancer
Eligibility Criteria
Inclusion Criteria: * Suspected or diagnosed disease * ≥60 years old patients, except for patients receiving high-dose chemotherapy and stem cell transplantion who need to be ≥18 years old * Cross-sectional imaging maximum 45 days prior to consenting or before the next treatment line * Patients with cancer (other than patients with prostate cancer treated with hormonal treatment before radiation treatment): study procedures (excluding image analyses) must have been carried out maximum 1 month prior to the start of a new treatment line * Patients with prostate cancers receiving hormonal treatment before radiation treatment): study procedures (excluding image analyses) must be carried out maximum 3 months after the start of hormonal treatment * Patients with other conditions: study procedures (excluding image analyses) must have been carried out maximum 4 days after the start of the hospitalization Exclusion Criteria: * Not willing or unable to give written consent * Patient not deemed suitable for the study by the researcher approaching the patient
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07740239 clinical trial?
This trial is open to male participants only, studying Pelvic Fracture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07740239 currently recruiting?
Yes, NCT07740239 is actively recruiting participants. Contact the research team at otso.arponen@tuni.fi for enrollment information.
Where is the NCT07740239 trial being conducted?
This trial is being conducted at Tampere, Finland.
Who is sponsoring the NCT07740239 clinical trial?
NCT07740239 is sponsored by Tampere University Hospital. The trial plans to enroll 2,050 participants.